IGF-1 LR3: Insulin-like Growth Factor - Scientific Guide

EXOMA Scientific Team · Publicado el 13 de abril de 2026 · Actualizado el 17 de agosto de 2026

IGF-1 LR3: extended half-life analog of insulin-like growth factor. Mechanism of action, comparison with MGF, PEG MGF y ACE-031.

What is IGF-1 LR3?

IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a synthetic analog of insulin-like growth factor 1 (IGF-1) with two key modifications that confer pharmacological properties superior to native IGF-1.

Structural Modifications

• Arg3 substitution: The glutamine at position 3 is replaced by arginine
• N-terminal extension: Addition of 13 amino acids at the N-terminal end
• Result: 83 amino acids vs. 70 of native IGF-1
• Molecular weight: ~9,111 Da

Functional Consequences

These modifications produce:

1. Drastic reduction in affinity for IGFBPs (proteínas de unión a IGF): ~1000x menor afinidad
2. Greater bioavailability: By not being sequestered by IGFBPs, more free IGF-1 LR3 is available to activate receptors
3. Extended half-life: 20-30 horas vs. ~15 minutos del IGF-1 nativo
4. Greater in vivo potency: 2-3x more potent than IGF-1 in proliferation assays

Mechanism of Action

Signaling via IGF-1R

IGF-1 LR3 activates the IGF-1 receptor (IGF-1R), a receptor tyrosine kinase:

1. Binding to IGF-1R: Dimerización y autofosforilación del receptor
2. Activation of IRS-1/2: Fosforilación de sustratos del receptor de insulina
3. PI3K/Akt pathway: Señalización de supervivencia celular y síntesis proteica
4. Ras/MAPK/ERK pathway: Proliferación celular y diferenciación
5. mTOR: Activation of the protein synthesis machinery

Biological Effects

The GH/IGF-1 Axis

To understand IGF-1 LR3, it is necessary to contextualize the somatotropic axis:

1. Hypothalamus → GHRH (estimulador) + Somatostatina (inhibidor)
2. Anterior pituitary → Secreción de GH
3. Liver → Producción de IGF-1 (endocrino)
4. Local tissues → IGF-1 production (autocrine/paracrine)

IGF-1 mediates approximately 70% of the anabolic effects attributed to GH.

Comparison with Related Growth Factors

MGF (Mechano Growth Factor)

MGF is a splice variant of IGF-1 (IGF-1Ec in humans):

• Origin: Expressed locally in muscle in response to mechanical stress
• Function: Activation of muscle satellite cells
• Mechanism: Signaling different from canonical IGF-1
• Half-life: Very short (~minutes) due to rapid degradation
• Action: Predominantly autocrine/paracrine

PEG MGF (PEGylated MGF)

Pegylated version of MGF for greater stability:

• Modification: Conjugated polyethylene glycol
• Half-life: Significantly greater than native MGF
• Distribution: Systemic vs. local of MGF
• Application: Muscle regeneration research

ACE-031 (Myostatin Decoy Receptor)

ACE-031 is not a growth factor but an inhibitor of myostatin signaling:

• Structure: ActRIIB-Fc fusion protein
• Mechanism: Sequesters myostatin, activin, and GDF-11
• Effect: Muscle hypertrophy via disinhibition
• Complementarity: Acts via a different pathway than IGF-1

Comparison Table

IGFBPs: Modulators of Activity

IGF-binding proteins (IGFBP-1 to IGFBP-6) regulate the bioavailability of IGF-1:

• IGFBP-3: Main plasma carrier (~75% of circulating IGF-1)
• IGFBP-5: Enhancer of IGF-1 activity in bone
• IGFBP-1: Regulated by insulin, it modulates postprandial IGF-1 activity

IGF-1 LR3 evades this regulatory system, which explains its greater potency but also the need for careful dosing in research.

Research Applications

Muscle Biology

• Studies of muscle hypertrophy and regeneration
• Activation of satellite cells
• Transition of type IIb → type IIa fibers

Neuroscience

• Neuroprotection and neurogenesis
• CNS myelination
• Research in neurodegenerative diseases

Metabolism

• Nutrient partitioning
• Insulin sensitivity
• Glucose metabolism

Technical Considerations

• Reconstitution: 0.1M acetic acid or bacteriostatic water
• Storage: -20°C (lyophilized), 2-8°C (reconstituted, max 30 days)
• Sensitivity: Avoid freeze-thaw cycles
• Incompatibilities: Avoid neutral/basic pH during storage

Conclusion

IGF-1 LR3 is the most potent and bioavailable form of IGF-1 available for research, thanks to its modifications that evade the regulatory system of IGFBPs. Together with MGF, PEG MGF and ACE-031, it forms an arsenal of tools for research on the regulation of tissue growth and protein synthesis.

Available at Exoma Peptides with certified COA.

References

Material for research use only. Verified primary sources supporting the scientific claims of this article:

1. Francis GL, Ross M, Ballard FJ, Milner SJ, Senn C, McNeil KA, Wallace JC, King R, Wells JR. Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. J Mol Endocrinol. 1992;8(3):213-223. doi:10.1677/jme.0.0080213. PMID 1378742. (in vitro)
2. Voorhamme D, Yandell CA. LONG R3IGF-I as a more potent alternative to insulin in serum-free culture of HEK293 cells. Mol Biotechnol. 2006;34(2):201-204. doi:10.1385/mb:34:2:201. PMID 17172665. (in vitro)
3. Conlon MA, Tomas FM, Owens PC, Wallace JC, Howarth GS, Ballard FJ. Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig. J Endocrinol. 1995;146(2):247-253. doi:10.1677/joe.0.1460247. PMID 7561636. (animal)
4. Tomas FM, Lemmey AB, Read LC, Ballard FJ. Superior potency of infused IGF-I analogues which bind poorly to IGF-binding proteins is maintained when administered by injection. J Endocrinol. 1996;150(1):77-84. doi:10.1677/joe.0.1500077. PMID 8708565. (animal)

Products available at EXOMA

• IGF-1 LR3